what matters most?
CAPTURING PATIENTS' PRIORITIES

What Matters Most to people with multiple myeloma?
Patient workshop outcomes

OXFORD
BLOOD GROUP

1. Can we better manage the short and long-term side effects of myeloma treatments?

2. How can we ensure that people with myeloma get the drug that best suits the genetic subtype of their disease?

3. How can we ensure that people have equal access to new myeloma treatments, regardless of whether or not they have private health insurance?

4. Can we identify a cure for multiple myeloma?

5. Can whole genome sequencing help the future of myeloma treatments?

what matters most?
CAPTURING PATIENTS' PRIORITIES

what matters most to people with multiple myeloma? patient workshop outcomes

OXFORD
BLOOD GROUP

6. How can we ensure that myeloma is diagnosed as early as possible?



7. What do we know about common factors in the history of people with myeloma, such as environmental, demographic, ethnic and family histories? How can we share this information with people who have or might develop myeloma?

8. Can we learn more about the long-term effects of prolonged cycles of treatment?

9. How can we maximise opportunities for people with myeloma to access new cellular / gene therapies?

10. How do we stratify risk and adapt treatments accordingly to prevent people being overtreated (for example using measures of MRD)?

what matters most?
CAPTURING PATIENTS' PRIORITIES

what matters most to people with multiple myeloma: things that just missed the top 10:

OXFORD
BLOOD GROUP

Can we identify an alternative to dexamethasone? Can we do more to titrate or individualise dexamethasone treatment to the individual? How can we ensure that people are not getting more dexamethasone than they need?

How can we ensure that people with myeloma know about and have access to clinical trials, regardless of where they live or are treated?

How can we prevent, or improve the management of, “chemo brain”

How can we prevent, or improve treatment of gastrointestinal side effects of transplant chemotherapy

How can we prevent, or improve treatment of peripheral neuropathy?

What is the impact of psychological support for myeloma patients and their families?